Poseida Therapeutics logo

Poseida Therapeutics Funding & Investors

Poseida Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company utilizes proprietary gene engineering platform technologies to create next generation cell and gene therapeutics.

poseida.com

Total Amount Raised: $435,449,984

Poseida Therapeutics Funding Rounds

  • Post Ipo Equity

    $25,000,000

    Post Ipo Equity Investors

    Astellas Pharma
  • Post Ipo Equity

    $25,000,000

    Post Ipo Equity Investors

    Astellas Pharma
  • Post Ipo Equity

    $70,000,000

  • Post Ipo Equity

    $70,000,000

  • Series D

    $110,000,000

    Series D Investors

    Schonfeld Strategic Advisors
    Adage Capital Management
    Fidelity Management and Research Company
  • Series D

    $110,000,000

    Series D Investors

    Schonfeld Strategic Advisors
    Adage Capital Management
    Fidelity Management and Research Company
  • Series C

    $142,000,000

    Series C Investors

    Novartis
    Rapha Capital Management
    Malin
    Vivo Capital
    Perceptive Advisors
    Longitude Capital
    Pentwater Capital Management
    Boxer Capital
    Aisling Capital
  • Series C

    $142,000,000

    Series C Investors

    Novartis
    Rapha Capital Management
    Malin
    Vivo Capital
    Perceptive Advisors
    Longitude Capital
    Pentwater Capital Management
    Boxer Capital
    Aisling Capital
  • Grant

    $3,990,000

    Grant Investors

    California Institute for Regenerative Medicine
  • Series B

    $30,500,000

    Series B Investors

    Malin
    Vivo Capital
    Tavistock Group
    Longitude Capital
  • Grant

    $3,990,000

    Grant Investors

    California Institute for Regenerative Medicine
  • Series B

    $30,500,000

    Series B Investors

    Malin
    Vivo Capital
    Tavistock Group
    Longitude Capital
  • Grant

    $19,800,000

    Grant Investors

    California Institute for Regenerative Medicine
  • Grant

    $19,800,000

    Grant Investors

    California Institute for Regenerative Medicine
  • Series A

    $11,160,002

    Series A Investors

    Malin
    Eric Ostertag
  • Series A

    $23,000,000

    Series A Investors

    Malin
    Eric Ostertag
  • Series A

    $11,160,002

    Series A Investors

    Malin
    Eric Ostertag
  • Series A

    $23,000,000

    Series A Investors

    Malin
    Eric Ostertag
Funding info provided by Diffbot.